These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 1974283)

  • 1. Neuroleptic malignant syndrome.
    Srinivasan AV; Murugappan M; Krishnamurthy SG; Sayeed ZA
    J Neurol Neurosurg Psychiatry; 1990 Jun; 53(6):514-6. PubMed ID: 1974283
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuroleptic malignant syndrome during abrupt reduction of neuroleptic treatment.
    Spivak B; Weizman A; Wolovick L; Hermesh H; Tyano S; Munitz H
    Acta Psychiatr Scand; 1990 Feb; 81(2):168-9. PubMed ID: 1970216
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuroleptic malignant syndrome induced by ziprasidone on the second day of treatment.
    Ozen ME; Yumru M; Savas HA; Cansel N; Herken H
    World J Biol Psychiatry; 2007; 8(1):42-4. PubMed ID: 17366349
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuroleptic malignant syndrome: a case report.
    Fekadu A; Wakwoya A
    Ethiop Med J; 1999 Jul; 37(3):195-8. PubMed ID: 11957317
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuroleptic Malignant Syndrome with ziprasidone.
    Murty RG; Mistry SG; Chacko RC
    J Clin Psychopharmacol; 2002 Dec; 22(6):624-6. PubMed ID: 12454565
    [No Abstract]   [Full Text] [Related]  

  • 6. Failed challenge with quetiapine after neuroleptic malignant syndrome with conventional antipsychotics.
    Hatch CD; Lund BC; Perry PJ
    Pharmacotherapy; 2001 Aug; 21(8):1003-6. PubMed ID: 11718487
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [A neuroleptic malignant syndrome complicated by subarachnoid hemorrhage and revealing cerebral vasculitis].
    Jouali T; Boukatta B; Bechri B; Houari N; Bouazzaoui A; Sbai H; Kanjaa N
    Pan Afr Med J; 2014; 19():247. PubMed ID: 25852790
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Poorly controlled EPS: risk factors for NMS.
    Primeau F; Fontaine R; Chouinard G
    Can J Psychiatry; 1987 May; 32(4):328, 331. PubMed ID: 2886211
    [No Abstract]   [Full Text] [Related]  

  • 9. [Neuroleptic malignant syndrome. Case reports].
    Berardi D; Troia M; Veronesi L; Ferrari G
    Minerva Psichiatr; 1994 Dec; 35(4):199-219. PubMed ID: 7861943
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Olanzapine induced neuroleptic malignant syndrome--a case review.
    Kogoj A; Velikonja I
    Hum Psychopharmacol; 2003 Jun; 18(4):301-9. PubMed ID: 12766935
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuroleptic malignant syndrome: life-threatening complication of neuroleptic treatment in adolescents with affective disorder.
    Joshi PT; Capozzoli JA; Coyle JT
    Pediatrics; 1991 Feb; 87(2):235-9. PubMed ID: 1670966
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Neuroleptic malignant syndrome and atypical antipsychotics: a brief review].
    Khaldi S; Kornreich C; Choubani Z; Gourevitch R
    Encephale; 2008 Dec; 34(6):618-24. PubMed ID: 19081460
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Atypical neuroleptic malignant syndrome in patients treated with aripiprazole and clozapine: a case-series study and short review.
    Tseng PT; Chang YC; Chang CH; Wang HY; Cheng YS; Wu CK; Chen YW; Chung W
    Int J Psychiatry Med; 2015; 49(1):35-43. PubMed ID: 25838319
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuroleptic malignant syndrome associated with the use of prochlorperazine in a patient with a recent history of antipsychotic-induced neuroleptic malignant syndrome.
    Musselman ME; Browning LA; Parker D; Saely S
    Ann Pharmacother; 2011 Nov; 45(11):e61. PubMed ID: 21972252
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neuroleptic malignant syndrome related to use of clozapine.
    Trayer JS; Fidler DC
    J Am Osteopath Assoc; 1998 Mar; 98(3):168-9. PubMed ID: 9558834
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NMS after clozapine initiation.
    Skarpathiotakis M; Westreich N
    J Am Acad Child Adolesc Psychiatry; 2005 Nov; 44(11):1101-2. PubMed ID: 16239854
    [No Abstract]   [Full Text] [Related]  

  • 17. Risk for definite neuroleptic malignant syndrome. A prospective study in 223 consecutive in-patients.
    Hermesh H; Aizenberg D; Weizman A; Lapidot M; Mayor C; Munitz H
    Br J Psychiatry; 1992 Aug; 161():254-7. PubMed ID: 1355693
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Probable case of neuroleptic malignant syndrome following administration of antituberculotic drugs in a chlorpromazine-treated patient.
    Shim G; Kang DH; Kwon JS
    J Korean Med Sci; 2008 Aug; 23(4):734-6. PubMed ID: 18756068
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuroleptic toxicity syndromes: a clinical spectrum.
    Reilly JJ; Crowe SF; Lloyd JH
    Aust N Z J Psychiatry; 1991 Dec; 25(4):499-505. PubMed ID: 1686547
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The application of electroconvulsive therapy in neuroleptic malignant syndrome treatment in patient with catatonic schizophrenia].
    Kucia K; Warchala A
    Wiad Lek; 2005; 58(9-10):572-4. PubMed ID: 16529073
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.